Press Release April 23, 2020

Accent Therapeutics Completes $63 Million Series B

The Life Sciences team advised Accent Therapeutics on the completion of its $63 million Series B financing. The Series B was led by EcoR1 Capital with participation by GV, AbbVie Ventures, The Mark Foundation for Cancer Research, NS Investment and Droia Ventures as well as existing investors, Atlas Venture and The Column Group. Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1, and to continue to expand its pipeline in the rich target space of RNA modification.

Launched in 2018, Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of RNA modification. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation.

The Goodwin team was led by William Collins, Gabriela Morales-Rivera and Mitchell Bloom.

For additional details on the financing round, please read the press release and coverage in FierceBiotech.